Therapeutic antibodies for autoimmunity and inflammation.
The development of therapeutic antibodies has evolved over the past decade into a mainstay of therapeutic options for patients with autoimmune and inflammatory diseases. Substantial advances in understanding the biology of human diseases have been made and tremendous benefit to patients has been gained with the first generation of therapeutic antibodies. The lessons learnt from these antibodies have provided the foundation for the discovery and development of future therapeutic antibodies. Here we review how key insights obtained from the development of therapeutic antibodies complemented by newer antibody engineering technologies are delivering a second generation of therapeutic antibodies with promise for greater clinical efficacy and safety.
Chan
Andrew C
AC
Department of Immunology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, USA. acc@gene.com
Carter
Paul J
PJ
D000818:Animals; D018033:Antibodies, Bispecific / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000920:Antibody-Dependent Cell Cytotoxicity; D001327:Autoimmune Diseases / Q000188:drug therapy*; D016207:Cytokines / Q000037:antagonists & inhibitors; D006207:Half-Life; D006801:Humans; D007249:Inflammation / Q000188:drug therapy*; D036341:Intercellular Signaling Peptides and Proteins / Q000276:immunology
D018033:Antibodies, Bispecific; D000911:Antibodies, Monoclonal; D016207:Cytokines; D036341:Intercellular Signaling Peptides and Proteins